The chimeric antigen receptor T(CAR-T)cell therapy is a new treatment for a variety of cancers.The idea is to take out the T-cells from the patient,and genetically engineer the cells to make them express a chimeric receptor(CAR)recognizing a specific tumor-associated antigen(TAAs).As a result,the CAR-expressing T cells,when reintroduced into the patient's body,will target and eliminate the TAA-expressing tumor cells.

Evaluating CAR expression is an essential step in the production of CAR-T cells.This is often done by flow cytometry,using protein L,anti-Fab antibodies or target antigens as detection antibodies.Among these common choices,target antigens are widely considered to be the best option,because it offers high specificity and minimal background staining.

ACROBiosystems has developed an extensive collection of recombinant proteins to support CAR-T therapy development.This growing list of proteins includes many fluorescent-labeled target antigens and pre-biotinylated proteins that are uniquely suitable for evaluation of CAR expression.In addition,we also supply hard-to-make proteins such as BCMA,CD19,ROR1,and EGFRVIII.